Araujo Castro, MartaBiagetti, BetinaMenéndez, EdelmiroNovoa Testa, IriaCordido, FernandoRodríguez Berrocal, VíctorPascual Corrales, EiderGuerrero Pérez, FernandoVicente, AlmudenaGarcía Centeno, RogelioGonzález Fernández, LauraOllero García, María DoloresIrigaray Echarri, AnaMoure Rodríguez, María DoloresNovo Rodríguez, CristinaCalatayud, MaríaVillar Taibo, RocíoBernabéu, IgnacioÁlvarez Escolá, CristinaTenorio Jimenéz, CarmenAbellán Galiana, PabloVenegas Moreno, EvaGonzález Molero, InmaculadaIglesias, PedroBlanco, ConcepciónVidal Ostos de Lara, FernandoMiguel Novoa, María de la Paz deLópez Mezquita Torres, ElenaHanzu, Felicia A.Lamas, CristinaAznar Rodríguez, SilviaAulinas, AnnaRecio Córdova, Jose M.Aviles Pérez, María DoloresSampedro Nuñez, Miguel AntonioCámara, RosaPaja Fano, MiguelFajardo Montañana, CarmenCardoso, LuísMarques, PedroMartínez Sáez, ElenaRuz Caracuel, IgnacioMarazuela, MónicaPuig Domingo, Manuel2025-09-052025-09-052025-07-012049-3614https://hdl.handle.net/2445/222962Aim: To evaluate which factors are associated with a higher probability of failure to surgical and first-generation somatostatin receptor ligands (fgSRLs) treatment in patients with growth hormone and prolactin co-secreting pituitary adenomas (GH&PRL-PAs). Methods: Acromegaly patients with GH&PRL-PAs included in the ACRO-SPAIN study were enrolled. GH&PRL-PAs were defined as tumors with serum PRL levels above the upper limit of normal and positive immunostaining for GH and PRL, or with PRL levels >= 100 ng/mL when immunostaining data were not available. Results: A total of 126 acromegaly patients with GH&PRL-PAs who underwent transsphenoidal pituitary surgery were included, and 42.1% (n = 53) were biochemically cured at the immediate postoperative evaluation. Knosp grade >2 (odds ratio (OR) 3.48, 95% CI 1.28-9.38), higher serum GH (OR 1.01, 95% CI 1.01-1.08) and IGF-1 (OR 1.60, 95% CI 1.05-2.45) levels were associated with a lower probability of surgical cure. Sixty-eight patients received first-line medical therapy as follows: fgSRLs in monotherapy (n = 22), fgSRL plus cabergoline (n = 37), cabergoline in monotherapy (n = 7) and pegvisomant in monotherapy (n = 2). Among the cases treated with fgSRL in monotherapy, 18.2% (n = 4/22) were resistant. We identified as predictors of fgSRL resistance (in monotherapy and combined with cabergoline) a Knosp grade >2 (OR 8.75, P = 0.003), high GH levels at acromegaly diagnosis (OR 1.02, P = 0.031) and higher postoperative GH levels (OR 1.05, P = 0.006), but no predictors of response to fgSRL in monotherapy were identified. Conclusion: The clinical predictors of surgical failure and of fgSRL resistance in patients with GH&PRL-PAs are similar to those described in acromegaly without PRL, co-secretion.11 p.application/pdfengcc-by (c) Araujo Castro, Marta et al., 2025http://creativecommons.org/licenses/by/3.0/es/Malalties de la hipòfisiCirurgia endocrinaTerapèuticaPituitary gland diseasesEndocrine surgeryTherapeuticsinfo:eu-repo/semantics/article2025-09-04info:eu-repo/semantics/openAccess40590355